SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 23, 2001
---------------
Generex Biotechnology Corporation
-------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
---------------------------- ----------------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
-----------------------------
-------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 4. Changes in Registrant's Certifying Accountant.
On April 23, 2001, the stockholders of Generex Biotechnology
Corporation ratified the selection and engagement of Deloitte & Touche L.L.P.
("Deloitte Touche") to serve as the independent public accountants to audit the
financial statements of Generex and its subsidiaries for the fiscal year ending
July 31, 2001. WithumSmith+Brown has been employed to perform this function for
Generex since September 1998.
The appointment of Deloitte Touche as independent public accountants replacing
WithumSmith+Brown was recommended by the Board of Directors of Generex.
WithumSmith+Brown did not decline to stand for re-election and
WithumSmith+Brown's reports on financial statements for the last two fiscal
years did not contain an adverse opinion, disclaimer of opinion or qualification
as to uncertainty, audit scope or accounting principles. There have been no
disagreements with WithumSmith+Brown in the last two fiscal years on any matter
of accounting principles or practices, financial statement disclosure or
auditing scope or procedure.
Item 7. Financial Statements and Exhibits
16. Letter from WithumSmith+Brown regarding the appointment of Deloitte
Touche as independent public accountants for Generex for the fiscal
year ending July 31, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: April 27, 2001 By: /s/ E. Mark Perri
--------------- ----------------------------------
E. Mark Perri, Chairman and CFO